The ups and downs that have marked IntraBiotics Pharmaceuticals Inc.’s recent history continued, as the company said the first glimpse of unblinded data from its Phase III iseganan hydrochloride oral solution showed the product fared poorly against placebo in primary and secondary endpoints, sending its stock crashing 69.5 percent. (BioWorld Today)

The ups and downs that have marked IntraBiotics Pharmaceuticals Inc.’s recent history continued, as the company said the first glimpse of unblinded data from its Phase III iseganan hydrochloride oral solution showed the product fared poorly against placebo in primary and secondary endpoints, sending its stock crashing 69.5 percent. (BioWorld Today)

Getting an unexpected agency response that may have little to do with how Cialis is meant to be used, ICOS Corp. and Eli Lilly and Co. said the FDA issued an approvable letter for their erectile dysfunction product in which it requested three issues be resolved, one being pharmacology studies. (BioWorld Today)

Getting an unexpected agency response that may have little to do with how Cialis is meant to be used, ICOS Corp. and Eli Lilly and Co. said the FDA issued an approvable letter for their erectile dysfunction product in which it requested three issues be resolved, one being pharmacology studies. (BioWorld Today)